Clinical Trials
12 trialsNCT01879657 2025-08-06
68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)
Radio Isotope Therapy of America
Phase NA Completed
NCT03448458 2025-07-17
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
Emory University
Phase 2 Completed
NCT03602911 2025-03-12
A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients
West Virginia University
Phase 2 Completed
NCT01873248 2024-07-19
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT05990998 2024-02-26
A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective Study
First Affiliated Hospital of Fujian Medical University
Phase 1/2 Completed
NCT03953131 2023-09-01
Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00001277 2022-06-07
Studies of Elevated Parathyroid Activity
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01869725 2021-09-22
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
University of Iowa
Phase 2 Completed
NCT01619865 2021-07-27
GA-68
University of Iowa
Phase 1/2 Completed
NCT03125629 2021-04-09
Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals
Stanford University
Phase 2 Completed
NCT03197012 2020-07-07
Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
University of California, San Francisco
Phase EARLY_PHASE1 Completed
NCT01967537 2019-11-19
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed